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A B S T R A C T
Purpose
The purpose of this study was to determine remission induction frequency when bortezomib was
combined with daunorubicin and cytarabine in previously untreated older adults with acute
myeloid leukemia (AML) and safety of bortezomib in combination with consolidation chemother-
apy consisting of intermediate-dose cytarabine (Int-DAC).
Patients and Methods
Ninety-five adults (age 60 to 75 years; median, 67 years) with previously untreated AML (including
therapy-related and previous myelodysplastic syndrome) received bortezomib 1.3 mg/m2 intrave-
nously (IV) on days 1, 4, 8, and 11 with daunorubicin 60 mg/m2 on days 1 through 3 and cytarabine
100 mg/m2 by continuous IV infusion on days 1 through 7. Patients who achieved complete
remission (CR) received up to two courses of consolidation chemotherapy with cytarabine 2
gm/m2 on days 1 through 5 with bortezomib. Three cohorts with escalating dose levels of
bortezomib were tested (0.7, 1.0, and 1.3 mg/m2). Dose-limiting toxicities were assessed during
the first cycle of consolidation. The relationship between cell surface expression of CD74 and
clinical outcome was assessed.
Results
Frequency of CR was 65% (62 of 95), and 4% of patients (four of 95) achieved CR with incomplete
platelet recovery (CRp). Eleven patients developed grade 3 sensory neuropathy. Bortezomib plus
Int-DAC proved tolerable at the highest dose tested. Lower CD74 expression was associated with
CR/CRp (P  .04) but not with disease-free or overall survival.
Conclusion
The addition of bortezomib to standard 3  7 daunorubicin and cytarabine induction chemotherapy
for AML resulted in an encouraging remission rate. The maximum tested dose of bortezomib
administered in combination with Int-DAC for remission consolidation was 1.3 mg/m2 and proved
tolerable. Further testing of this regimen is planned.
J Clin Oncol 31:923-929. © 2012 by American Society of Clinical Oncology
INTRODUCTION
Remission induction chemotherapy with cytarabine
and an anthracycline has been a standard treatment
for newly diagnosed acute myeloid leukemia (AML)
for more than 30 years. The complete remission
(CR) rate for patients with AML age  60 years is
40% to 60%, and several strategies have been em-
ployed to intensify the induction regimen in the
hope of improving the remission rate; however,
none have provided a clear advantage to induction
therapy with cytarabine and an anthracycline.1-3
Therefore, agents capable of improving on existing
regimens with minimal added toxicity are clearly
needed for this age group.
Bortezomib is a potent, reversible, and spe-
cific inhibitor of the proteasome, a target for
antineoplastic agents.4 By inhibiting the protea-
some, bortezomib has been demonstrated to in-
hibit the master transcription factor nuclear
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factor-kappa B (NF-B), which is increased in the active form in
AML cells5-7 and leukemia stem cells (LSCs).5,8
We previously demonstrated that bortezomib can be safely
added to induction chemotherapy in patients with relapsed or
refractory AML, resulting in an encouraging remission rate.9 We
also previously demonstrated that expression of CD74, the major
histocompatibility complex class II chaperone molecule and recep-
tor for macrophage migration inhibitory factor (MIF), which sig-
nals via NF-B and other molecules,10 was associated with clinical
outcome in patients with AML treated with bortezomib, idarubi-
cin, and cytarabine.9,11
The goal of this study was to determine the CR rate in older
patients with AML treated with bortezomib plus daunorubicin and
cytarabine and the maximum-tolerated dose (MTD) of bortezomib
when added to intermediate-dose cytarabine (Int-DAC). We also
sought to determine the disease-free (DFS) and overall survival (OS)
of patients in this study and the relationship between CD74 expression
and clinical outcome.
PATIENTS AND METHODS
Eligibility for the study was restricted to patients age 60 to 75 years with
previously untreated AML. An unequivocal histologic diagnosis of AML based
on WHO criteria ( 20% blasts in bone marrow) was required. Acute promy-
elocytic leukemia was excluded. Patients with therapy-related AML and pre-
vious myelodysplastic syndrome (MDS) and myeloproliferative neoplasm
(MPN) were eligible. Additional eligibility information is provided in the
Appendix (online only).
Treatment
For remission induction, bortezomib 1.3 mg/m2 was administered by
rapid intravenous (IV) bolus (3 to 5 seconds) on days 1, 4, 8, and 11. Bort-
ezomib was the first drug to be administered on day 1, 1 hour before dauno-
rubicin. It was recommended that bortezomib be administered at the same
time on days 4, 8, and 11 as on day 1  approximately 2 hours. Daunorubicin
60 mg/m2/d was administered by IV injection or short IV infusion on days 1
through 3 at approximately the same time daily. The dose of daunorubicin was
reduced if the bilirubin level was elevated (daunorubicin was reduced by 25%
for total bilirubin between 2 and 3 mg/dL and by 50% for total bilirubin  3
mg/dL). Cytarabine 100 mg/m2/d was administered by continuous IV infu-
sion on days 1 through 7 and was started after bortezomib and daunorubicin
were administered on day 1. Bone marrow examination was performed on day
18  1 day. Day 18, rather than day 14, was selected to allow for an interval of
7 days from the last chemotherapy administration (day 11 bortezomib) to the
assessment of bone marrow. Patients with residual leukemia received a second
course of remission induction chemotherapy, which consisted of bortezomib
1.3 mg/m2 on days 1 and 4, daunorubicin 60 mg/m2/d on days 1 through 2,
and cytarabine 100 mg/m2/d by continuous IV infusion on days 1 through 5.
Bone marrow examination (aspirate and biopsy) was required within 1 week
of recovery of the absolute neutrophil count  1,000/L and platelets
 100,000/L, but no later than day 42 of the final induction course.
Patients who achieved CR or partial remission (PR; defined as meet-
ing criteria for CR but with reduction in bone marrow blasts by  50% to
5% to 25%) were eligible to receive consolidation therapy, as were patients
achieving CR with incomplete platelet recovery (CRp; defined as meeting
criteria for CR but with platelet count  100,000/L) who recovered
platelets to  100,000/L within 4 weeks of achieving CRp. Patients were
reregistered through the Alliance Statistics and Data Center for the phase II
portion of the trial.
During consolidation chemotherapy, the dose of bortezomib was esca-
lated in cohorts. Bortezomib dose cohorts were assigned at the time of regis-
tration to remission consolidation therapy. Bortezomib was administered on
days 1, 4, 8, and 11 and was the first drug to be administered on day 1.
Beginning 1 hour after bortezomib on day 1, cytarabine 2 g/m2 by IV infusion
over 3 hours once daily was administered on days 1 through 5. Before the
cytarabine infusion, corticosteroid ophthalmic solution two drops to each eye
4 daily was initiated and continued for at least 24 hours after the final dose
of cytarabine.
Patients were enrolled in one of three consecutive bortezomib dose
cohorts, each consisting of three to six patients. The three dose cohorts of
bortezomib assessed were: 0.7, 1.0, and 1.3 mg/m2. Enrollment in a cohort
ceased until all three patients in a cohort could be fully assessed for
treatment-related toxicities. If a cohort already contained three patients
currently undergoing evaluation for dose-limiting toxicity (DLT), subse-
quent patients were treated at the previous cohort dose of bortezomib
already tested. If no DLTs were experienced by the first three patients, the
dose was escalated to the next level. If one DLT was experienced among the
first three patients, an additional three patients were enrolled at the same
dose level. If  two DLTs were experienced among these six patients, dose
escalation was permitted. If  two DLTs were experienced among three to
six patients at a given dose level, the previous lower dose was declared the
MTD. Once the maximally tolerated, or maximally tested, dose of bort-
ezomib was identified, at least 10 additional patients were to be treated with
Int-DAC in combination with bortezomib at this dose. The maximum
planned dose of bortezomib was 1.3 mg/m2.
Patients who experienced bortezomib-related neuropathic pain and/or
peripheral sensory neuropathy were managed according to dose-reduction
and discontinuation guidelines set forth in the protocol. DLTs were considered
only during the first cycle of consolidation therapy and included grade 3 or 4
sensory or autonomic neuropathy, persistent grade 4 thrombocytopenia or
neutropenia at day 42 in the absence of AML, any grade 4 or 5 nonhematologic
toxicity, and any grade 3 nonhematologic toxicity (excluding neuropathy and
toxicities secondary to neutropenia and sepsis) that did not resolve to grade 2
by day 42 unless attributable to persistent or recurrent AML. Grade 4 anorexia
(requiring total parenteral nutrition) and grade 4 fatigue (requiring bed rest)
are commonly observed in older patients during AML treatment and were not
considered DLTs.
For patients who completed the first consolidation cycle without DLT
and without development of new grade  3 nonhematologic or infectious
toxicities, a second cycle of consolidation chemotherapy was administered
using the same dose of bortezomib used in the first cycle. Some patients
discontinued protocol treatment to pursue allogeneic hematopoietic cell
transplantation (alloHCT). All treated patients were observed for DFS, OS,
and event-free survival (EFS).
Statistical Analyses
There were two treatment components to this phase II/I trial: one,
remission induction chemotherapy consisting of bortezomib at a previously
established dose combined with daunorubicin and cytarabine (ie, 3  7),
followed by two, remission consolidation chemotherapy with a dose escalation
of bortezomib administered with Int-DAC.
The primary clinical end point for the remission induction portion of the
trial was complete response (CR and CRp). The primary end point of the
dose-escalation portion of the trial was the determination of DLT and identi-
fication of the MTD of bortezomib when combined with Int-DAC. The
secondary clinical end points were: one, to define the toxicities of bortezomib
when combined with intermediate-dose cytarabine, and two, to define DFS
and OS of patients treated in this study.
Regarding the induction phase, previous studies have suggested a
50% CR rate for a similar older patient population treated with comparable
3  7 chemotherapy.12 Therefore, the phase II portion of this trial was
designed to discriminate between true CR rates of no more than 45% and
at least 65%. Regarding the consolidation phase, an initial dose finding
phase was used to establish the MTD combination of bortezomib and
Int-DAC. Information regarding definitions, cytogenetic analysis, assess-
ment of CD74 expression levels, and statistical analyses is provided in the
Appendix (online only).
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RESULTS
Patient Characteristics
Ninety-eight patients age 60 to 75 years were enrolled between
September 15, 2008, and February 26, 2010, at 15 CALGB (Cancer and
Leukemia Group B) member institutions and their affiliated hospitals.
Three patients did not begin treatment and were excluded from all
analyses. Baseline characteristics for the 95 treated patients are listed in
Table 1.
Response to Induction Chemotherapy
Among the first 45 patients, 30 (67%) achieved CR, thereby
excluding a true CR incidence of  45%. Among all 95 patients, CR
frequency was 65% (62 of 95); an additional 4% of patients (four of
95) achieved CRp. Twenty-nine patients (31% of total) received a
second cycle of induction therapy; 17 of these patients (59% of this
group) achieved CR. Response rates by type of AML and ELN (Euro-
pean LeukemiaNet) genetic group classification are shown in Tables 2.
There was no statistically significant difference in CR rate by AML type
according to ELN group. Of eight patients with FLT3-ITD, six (75%)
achieved CR.

















Pacific Islander 1 1
Other 4 4
AML type
De novo 74 78
Therapy related 7 7






Abbreviations: AML, acute myeloid leukemia; ELN, European LeukemiaNet;
MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm.
Total may exceed 100% because of rounding.
†Available for 71 patients.






No. % No. % No. %
Type of AML
De novo 74 48 65 3 4 1 1
Therapy related 7 6 86 1 14 0 0
After MDS/MPN 14 8 57 0 0 1 7
All 95 62 65 4 4 2 2
ELN genetic group
Favorable 10 9 90 0 0 0 0
Intermediate-I 17 12 71 1 6 0 0
Intermediate-II 33 17 52 2 6 0 0
Adverse 11 5 45 1 10 0 0
Abbreviations: AML, acute myeloid leukemia; CR, complete remission; CRp,
complete remission with incomplete platelet recovery; ELN, European Leu-
kemiaNet; MDS, myelodysplastic syndrome; MPN, myeloproliferative neo-
plasm; PR, partial response.
Table 3. Maximal Grade  3 Nonhematologic and Noninfectious Toxicities
Occurring in  10% of Patients
Treatment Phase
Grade 3 Grade 4 Grade 5
No. % No. % No. %





Hypokalemia 12 13 3 3
Dyspnea 11 12 2 2
Hypoxia 6 6 5 5
Consolidation one (n  41)
Hypotension 5 12 1 2
Fatigue 4 10
Muscle weakness 4 10
Pain 5 12
Table 4. All Grade Neuropathies According to Treatment Phase
Treatment Phase
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
No. % No. % No. % No. % No. %
Induction (n  95)
Cranial 0 0 0 0 0 0 1 1 0 0
Motor 0 0 0 0 4 4 1 1 0 0
Sensory 9 10 4 4 6 6 0 0 0 0
Re-induction (n  29)
Cranial 0 0 0 0 0 0 0 0 0 0
Motor 0 0 0 0 0 0 0 0 0 0
Sensory 5 17 2 7 3 10 0 0 0 0
Consolidation one (n  41)
Cranial 0 0 0 0 0 0 0 0 0 0
Motor 0 0 0 0 0 0 0 0 0 0
Sensory 5 12 5 12 2 5 0 0 0 0
Consolidation two (n  25)
Cranial 0 0 0 0 0 0 0 0 0 0
Motor 0 0 0 0 0 0 0 0 0 0
Sensory 4 16 4 16 1 4 0 0 0 0
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Consolidation Treatment
Of the 62 patients who achieved CR, 41 received at least one cycle
of consolidation. Twenty-five patients received two cycles of consoli-
dation. One patient whose best response was PR also received one
cycle of consolidation.
During consolidation, there were no DLTs within each of the first
two three-person cohorts treated with bortezomib 0.7 and 1.0 mg/m2,
respectively. One of the first three patients treated with Int-DAC and
bortezomib 1.3 mg/m2 sustained a DLT of grade 3 sensory neuropa-
thy. There were no DLTs in the second cohort of three patients treated
with bortezomib 1.3 mg/m2 and Int-DAC. Therefore, an additional 11
patients were treated with 1.3 mg/m2 in consolidation.
Treatment Toxicities
In induction, 96% of patients had grade 4 hematologic toxicity
during induction. In addition, there were 51 patients with grade 3 and
three patients with grade 4 febrile neutropenia. There were 40 patients
with grade 3 and two patients with grade 4 clinically documented
infections. There were eight deaths in induction, six in primary induc-
tion (one resulting from pulmonary hemorrhage; three, infection;
one, cerebral vascular accident; and one, respiratory failure), and two
in reinduction (both resulting from infection).
In consolidation, 98% of patients had grade 4 hematologic tox-
icity. There were 15 patients with grade 3 and one patient with grade 4
febrile neutropenia and 12 patients with grade 3 and two patients with
grade 4 clinically documented infections. There was one treatment-
related death resulting from infection during consolidation. Nonhe-
matologic and noninfectious toxicities of grade  3 occurring in at
least 10% of patients are listed in Table 3.
Neuropathy
All patients received bortezomib during cycle one of induction,
and 97% of the 29 patients receiving a second induction course re-
ceived bortezomib (3% did not receive bortezomib because of neu-
ropathy). Table 4 indicates all grade neuropathies reported. There
were 11 patients who developed grade 3 sensory neuropathy at some
point during therapy. Six of these were during the first induction cycle,
three during the second induction cycle, and two during consolida-
tion. In general, investigators reported that neuropathy lessened or
resolved within weeks of treatment; however, long-term grade 1 sen-
sory neuropathy persisted in several patients.
Survival and Long-Term Follow-Up
Median follow-up time for the 34 patients still alive was 22
months (range, 11 to 30 months). Treatment outcomes and progres-
sion to consolidation and alloHCT are provided in Figure 1. Median
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Fig 1. Flow chart indicating patient outcome, treatment-related deaths, and occurrence of grade 3 sensory neuropathy. Allo HCT, allogeneic hematopoietic cell transplantation; CR,
complete remission; CRp, complete remission with incomplete platelet recovery; CVA, cerebral vascular accident; PR, partial response; SN, sensory neuropathy.
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Twenty-five patients received an allogeneic transplant. Of these
25 patients, 18 underwent alloHCT while in first CR, and their esti-
mated DFS and OS at 24 months are 54% (95% CI, 28% to 74%) and
52% (95% CI, 25% to 73%), respectively.
For the 48 patients who achieved CR or CRp and did not undergo
alloHCT, median DFS and OS were 7.4 and 17.5 months, respectively.
The estimated OS at 24 months is 36% (95% CI, 20% to 51%); the
estimated DFS at 24 months is 19% (95% CI, 7% to 36%). ELN genetic
group was not significantly correlated with EFS, DFS, or OS.
Relationship of CD74 Expression to Clinical Outcome
The median percentage of CD74 cells (28%; range, 0% to 95%)
was significantly lower in patients with CR/CRp than in those who did
not respond to therapy (52%; range, 2% to 97%; P  .040). The
median CD74 molecules of equivalent fluorescein (MEFS) for pa-
tients who achieved CR/CRp (7,232; range, 15 to 223,987) was also
lower compared with patients who did not respond (16,551; range,
929 to 201,985; P  .086). Neither CD74 expression nor MEFS was
correlated with patient age, WBC, or percentage of blood or bone
marrow blasts. Neither CD74 expression nor MEFS was correlated
with DFS, OS, or EFS.
CD74 expression on blast cells by MEFS, although not the per-
centage of cells expressing CD74, was associated with ELN genetic
group (P  .045 v .166). Given the relatively small number of patients
within each genetic group, we combined favorable and intermediate-I
into one combined group and intermediate-II and adverse into a
second combined group for the purpose of determining if increased
CD74 expression correlated with progressively worse combined
group. In this analysis, increased CD74 by both percentage of cells
expressing CD74 (P  .034) and CD74 expression according to MEFS
(P  .015) was significantly associated with worse combined group.
DISCUSSION
In this study, which enrolled older adults with newly diagnosed and
secondary AML, we assessed the CR rate when bortezomib was added
to standard induction chemotherapy consisting of daunorubicin and
cytarabine and determined the safety of bortezomib when added to
intermediate-dose cytarabine chemotherapy in consolidation. We
also assessed the relationship between CD74 expression by flow cy-
tometry and clinical outcome.
The combination of bortezomib with daunorubicin and cytara-
bine in induction resulted in an encouraging remission frequency of
65%, with an additional 4% CRp. A similar remission frequency was
seen in our previous study of bortezomib combined with idarubicin
and cytarabine in patients with relapsed AML and older adults with de
novo disease, in which CR and CRp rates of 61% and 10% were
observed, respectively. These remission frequencies are high relative to
those in recent studies12 and may have resulted from the addition of
bortezomib to the 3  7 regimen. Bortezomib is able to induce cyto-
toxicity in vitro in AML cells resistant to daunorubicin, and further-
more, bortezomib induces synergistic cytotoxicity when combined
with anthracyclines13 and antimetabolites.14,15 In addition, protea-
some inhibition has been demonstrated to induce LSC cytotoxicity.8
Whether one of these mechanisms or others may have contributed to
the favorable CR rate observed in this study will need to be explored in
future clinical trials.
We established that bortezomib up to 1.3 mg/m2 has an accept-
able toxicity profile when combined with Int-DAC during consolida-
tion. This observation is consistent with other studies in patients with
mantle-cell lymphoma, in which bortezomib was well tolerated when
added to single-agent cytarabine16 and the R-HyperCVAD (rituximab
plus hyperfractionated cyclophosphamide, vincristine, doxorubicin,
and dexamethasone) regimen.17
Grade 3 sensory neurotoxicity was observed in 11 patients.
Neurotoxicity is frequently observed with bortezomib in multiple
myeloma, but typically only after multiple cycles. Possible expla-
nations for the neurotoxicity observed in this study may relate to
the more intensive treatment required for AML; coadministration
with cytarabine, which is potentially neurotoxic at higher doses; or
effects of concomitant medications such as antifungal agents used in
the treatment of AML. Strategies such as altering the route of admin-
istration of bortezomib from IV to subcutaneous, changing the sched-
ule from twice to once per week, or using other proteasome inhibitors
with less neurotoxicity, such as carfilzomib, may reduce neurotoxicity
without sacrificing clinical efficacy; these approaches warrant investi-
gation in future clinical studies.
We assessed the relationship between CD74 expression by flow
cytometry and found that lower levels were significantly correlated
with increased CR/CRp and favorable ELN genetic groups. We used
flow cytometry to assess CD74 expression rather than gene expression
























































Fig 2. Survival plots and 95% CIs indicating (A) disease-free and (B) overall
survival of patients treated in this study.
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time consuming than microarray gene expression profiling. The rela-
tionship between CD74 and CR/CRp differs with that in a previous
smaller study of 31 patients with AML treated with bortezomib, ida-
rubicin, and cytarabine,6 possibly because of differences between in-
tracellular and cell surface expression of CD74. In other studies,
increased CD74 expression by microarray has been significantly cor-
related with adverse DFS/OS,11 as has increased expression of the
CD74 fragment CLIP.18,19 In this study, we did not observe a signifi-
cant relationship between CD74 and DFS/OS, possibly because a
substantial number of patients went on to undergo alloHCT. Taken
together, however, our current findings raise the possibility that the
CD74 expression levels on AML blasts at diagnosis may potentially
serve as a novel marker capable of identifying patients likely to achieve
CR/CRp with the combination of daunorubicin, cytarabine, and bort-
ezomib. Additional studies will be required to determine if CD74 is
associated with ELN genetic group.
We examined the safety and efficacy of bortezomib in combina-
tion with AML induction and consolidation chemotherapy because
bortezomib interacts synergistically with chemotherapeutic agents to
induce apoptosis in leukemia cells and because proteasome inhibition
has been demonstrated to target LSCs in vitro and in models of LSC
function. We demonstrated that the combination of bortezomib with
3  7 chemotherapy results in an encouraging remission frequency,
that bortezomib 1.3 mg/m2 has acceptable toxicity with Int-DAC in
consolidation, and that CD74 expression by flow cytometry is in-
versely correlated with complete remission. A phase III study in which
patients are randomly assigned to receive bortezomib or a double-
blinded placebo would be required to define the specific clinical ben-
efit of bortezomib with induction and consolidation chemotherapy.
Because bortezomib was recently demonstrated to downregulate
FLT3 expression,20 this study design would also permit testing the
effect of bortezomib on FLT3 levels and LSC populations.
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